[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-344645-105":59,"doc-detail-344645-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","glutamate-metabotropic-receptor-4-in-breast-cancer-a-potential-and-specific-target-for-chimeric-antigen-receptor-therapy","Glutamate metabotropic receptor 4 in breast cancer - a potential and specific target for chimeric antigen receptor therapy","","Glutamate metabotropic receptor 4 (GRM4) is identified as a novel chimeric antigen receptor (CAR)-associated target for breast cancer to overcome limitations of solid-tumor CAR-T therapy. Integrative multi-database screening prioritized GRM4, which was validated using human protein atlas data and expression assays across non-malignant organs and breast cancer cell lines, including IHC, western blot, qPCR, and immunofluorescence. In 158 paired clinical samples, GRM4 showed tumor-predominant membrane/cytoplasmic expression in 80.38% of patients while being absent in normal and para-cancerous tissues and restricted mainly to the brain in non-malignant organs. GRM4 related to advanced stage and age, with pan-subtype applicability and potential on-target off-tumor impact.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/glutamate-metabotropic-receptor-4-in-breast-cancer-a-potential-and-specific-target-for-chimeric-antigen-receptor-therapy/344645/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/glutamate-metabotropic-receptor-4-in-breast-cancer-a-potential-and-specific-target-for-chimeric-antigen-receptor-therapy/344645.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is GRM4 proposed as a CAR-T target for breast cancer?","Question",{"text":112,"@type":113},"GRM4 is highlighted as having breast-cancer-predominant membrane expression and restricted normal tissue distribution, aiming to reduce on-target off-tumor toxicity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was GRM4 prioritized and experimentally validated?",{"text":117,"@type":113},"GRM4 was prioritized by integrative multi-database analysis and then validated using Human Protein Atlas data, immunohistochemistry in organs and clinical samples, and assays including western blot, qPCR, and immunofluorescence in breast cancer cell lines.",{"name":119,"@type":110,"acceptedAnswer":120},"What expression pattern of GRM4 was observed in clinical samples?",{"text":121,"@type":113},"GRM4 showed tumor-specific membrane/cytoplasmic expression in 80.38% of breast cancer patients across subtypes, while it was absent in normal breast and para-cancerous tissues.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},344645,1790872342,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","TYPE Original Research PUBLISHED 07 January 2026 DOI 10.3389/fonc.2025.1654977  \nOPEN ACCESS  \nEDITED BY  \nMargaret Ottaviano,  \nG. Pascale National Cancer Institute Foundation (IRCCS), Italy  \nREVIEWED BY  \nMartina Pagliuca,  \nGustave Roussy Cancer Campus, France Arianna Draghi,  \nHerlev Hospital, Denmark  \n*CORRESPONDENCE  \nPingnan Sun  \n [pnsun@stu.edu.cn](pnsun@stu.edu.cn)[ ](pnsun@stu.edu.cn)Jundong Wu  \n [wujundong@stu.edu.cn](wujundong@stu.edu.cn)  \n†These authors have contributed equally to this work  \nRECEIVED 27 June 2025  \nREVISED 27 November 2025  \nACCEPTED 03 December 2025  \nPUBLISHED 07 January 2026  \nCITATION  \nXu Y, Hayierhan A, Chen Z, Ma Y, Zhang W, Xu C, Mei R, Zhou X, Zhu Y, Sun P and Wu J (2026) Glutamate metabotropic receptor 4 in breast cancer: a potential and speciﬁc target for chimeric antigen receptor therapy.  \nFront. Oncol. 15:1654977 .  \ndoi: 10.3389/fonc.2025.1654977  \nCOPYRIGHT  \n© 2026 Xu, Hayierhan, Chen, Ma, Zhang, Xu, Mei, Zhou, Zhu, Sun and Wu. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nGlutamate metabotropic receptor 4 in breast cancer:  \na potential and speciﬁc target for chimeric antigen receptor therapy  \nYien Xu 1,2†, Ayidana Hayierhan 3,4†, Zexiao Chen 1,4†, Yumei Ma 3,4, Wenjun Zhang 3,4, Chaoliang Xu 3,4, Ruyi Mei 3,4, Xiaoling Zhou 3,4, Yuhao Zhu 1,4, Pingnan Sun 3,5* and Jundong Wu 1,4*  \n1The Breast Center, Cancer Hospital of Shantou University Medical College, Shantou,  \nGuangdong, China, 2 Department of Radiation Oncology, Shantou Central Hospital, Shantou, Guangdong, China, 3Stem Cell Research Center, Shantou University Medical College, Shantou, Guangdong, China, 4Shantou University Medical College, Shantou, Guangdong, China, 5 Department of Gynecology of the First Afﬁliated Hospital, Shantou University Medical College, Shantou, Guangdong, China  \nBackground: Despite the revolutionary success of chimeric antigen receptor (CAR) therapy in hematologic malignancies, its application in solid tumors is hindered by the scarcity of tumor-speciﬁc membrane antigens rigorously validated in clinical specimens. Here, we identiﬁed glutamate metabotropic receptor 4 (GRM4) as a novel target with dual advantages: breast cancer (BC) -predominant membrane expression and restricted normal tissue distribution, potentially circumventing on-target off-tumor toxicity.  \nMethods: Through integrative multi-database analysis (DESeq2/edgeR/limma differential screening, CellMarker ﬁltration, the Human Protein Atlas database validation), GRM4 was prioritized. Its expression was validated in non-malignant organs [immunohistochemistry (IHC)], BC cell lines [western blot (WB)/ quantitative polymerase chain reaction (qPCR)/immunoﬂuorescence (IF)], 158 BC clinical samples with paired para-cancerous tissues (IHC) . Subcellular localization, tumor proportion score, and subtype-speciﬁc distribution were analyzed. Clinical correlations and survival outcomes were evaluated using chisquare tests and Kaplan-Meier analysis.  \nResults: Membrane expression was conﬁrmed by IHC in 35 .44% of clinical cases, and its presence in breast cancer cell lines was validated by WB, qPCR, and IF. GRM4 exhibited tumor-speciﬁc membrane/cytoplasmic expression in 80.38% of BC patients (127/158) across all subtypes (≥70% positivity), with 51.27% showing >50% tumor cell positivity. Critically, GRM4 was absent in normal breast/para-cancerous tissues and conﬁned to the brain in non-malignant organs. While GRM4 correlated with advanced clinical stage (p=0.025) and age (p=0.026), it was independent of overall survival (p=0 .449) .  \nFrontiers ","cbCaivtEylHuqlnF","https://ap.wps.com/l/cbCaivtEylHuqlnF","pdf",5843279,13,"English","# Background\n# Methods\n# Results\n# Conclusions\n# Keywords\n## breast cancer\n## CAR-T\n## GRM4\n## solid tumor\n## tumor-specific antigen","[{\"question\":\"Why is GRM4 proposed as a CAR-T target for breast cancer?\",\"answer\":\"GRM4 is highlighted as having breast-cancer-predominant membrane expression and restricted normal tissue distribution, aiming to reduce on-target off-tumor toxicity.\"},{\"question\":\"How was GRM4 prioritized and experimentally validated?\",\"answer\":\"GRM4 was prioritized by integrative multi-database analysis and then validated using Human Protein Atlas data, immunohistochemistry in organs and clinical samples, and assays including western blot, qPCR, and immunofluorescence in breast cancer cell lines.\"},{\"question\":\"What expression pattern of GRM4 was observed in clinical samples?\",\"answer\":\"GRM4 showed tumor-specific membrane/cytoplasmic expression in 80.38% of breast cancer patients across subtypes, while it was absent in normal breast and para-cancerous tissues.\"}]","Glutamate metabotropic receptor 4 in breast cancer - a potential and specific target for chimeric antigen receptor therapy | PDF",1790054754,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0a279b019d0200ff0b392608bf516f89.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/34a68112e711fb8761a8de65280d371d.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b6b49f9220e96ec9bd3f765d72b0a90.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/955afb1ea9410f15a1d82f0db86e867a.webp",980,1385]